Plasmodium vivax malaria relapses at a travel medicine centre in Rio de Janeiro, a non-endemic area in Brazil

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Pedro, Renata S ^a,b   Guaraldo, Lusiele ^a,b   Campos, Dayse P ^a   Costa, Anielle P ^a,b   Daniel Ribeiro, Cláudio T ^b,c   Brasil, Patrícia ^a,b  

^a Funda??o Oswaldo Cruz   (Brazil)

^b MINISTÉRIO DA SAÚDE   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Plasmodium vivax malaria; Relapse; Therapeutic failure; Weight based dosing

Indexed keywords

ARTESUNATE PLUS MEFLOQUINE; CHLOROQUINE; MEFLOQUINE; PRIMAQUINE; ANTIMALARIAL AGENT;

ARTICLE; BRAZIL; EMPORIATRICS; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PLASMODIUM VIVAX MALARIA; RECURRENT DISEASE; RELAPSE; SURVIVAL; TREATMENT RESPONSE; ADOLESCENT; ADULT; ANIMAL; FEMALE; MALE; MIDDLE AGED; RISK FACTOR; TREATMENT FAILURE;

ADOLESCENT; ADULT; ANIMALS; ANTIMALARIALS; BRAZIL; FEMALE; HUMANS; MALARIA, VIVAX; MALE; MIDDLE AGED; PRIMAQUINE; RECURRENCE; RISK FACTORS; TREATMENT FAILURE; YOUNG ADULT;

EID: 84864220159     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-245     Document Type: Article

References (45)

1. Malaria in Brazil: an overview. Oliveira-Ferreira J, Lacerda MVG, Brasil P, Ladislau JLB, Tauil PL, Daniel-Ribeiro CT, Malar J 2010 9 115 10.1186/1475-2875-9-115 20433744
2. Paludisme d Plasmodium vivax en Amazonie brésilienne: quelques aspects de son épidémiologie, de ses manifestations cliniques et des réactions immunitaires naturellement acquises. Daniel-Ribeiro CT, Lacerda MGV, Oliveira-Ferreira J, Bull Soc Path Exot 2008 101 243 248
3. Brasil, Ministério da Saúde, Situação epidemiolágica da malária no Brasil, ano de 2007 Ministério da Saúde, Brasília 2008 12613646
4. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Baird JK, Leksana B, Masbar S, Fryauff DJ, Sutanihardja MA, Suradi F, Wignall FS, Hoffman L, AmJTrop Med Hyg 1997 56 Suppl 6 621 626
5. Diagnástico tardio da malária em área endêmica de dengue na extra-Amazônia Brasileira: experiência recente de uma unidade sentinela no estado do Rio de Janeiro. Costa AP, Bressan CS, Pedro RS, Valls-de-Souza R, Silva S, Souza PR, Guaraldo L, Ferreira-da-Cruz MF, Daniel-Ribeiro CT, Brasil P, Rev Soc Bras Med Trop 2010 43 571 574 10.1590/S0037-86822010000500020 21085872
6. Lacerda MVG, Manifestaçes clínicas e patogênses da plaquetopenia na malária. PhD Thesis Universidade de Brasília, Brasília 2007 21089014
7. Two cases of Plasmodium vivax malaria with the clinical picture resembling toxic shock. Joon Young S, Cheong Won P, You Mee J, Jeong Yun K, Jeong Hyun K, Hyo Joong Y, Chi Hoon K, Chae Seung L, Hee Jin C, Woo Joo K, AmJTrop Med Hyg 2007 77 609 611
8. Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum. Karyana M, Burdarm L, Yeung S, Kenangalem E, Wariker N, Maristela R, Umana KG, Vemuri R, Okoseray MJ, Penttinen PM, Ebsworth P, Sugiarto P, Anstey NM, Tjitra E, Price RN, Malar J 2008 7 148 10.1186/1475-2875-7-148 18673572
9. Resistance to therapies for infection by Plasmodium vivax. Baird JK, Clin Microbiol Rev 2009 22 508 534 10.1128/CMR.00008-09 19597012
10. Short report: primaquine-tolerant Plasmodium vivax in an Italian traveler from Guatemala. Signorini L, Matteelli A, Castelnuovo F, Castelli F, Oladeji O, Carosi G, AmJTrop Med Hyg 1996 55 472 473
11. Brasil, Ministério da Saúde, Manual de Terapêutica da Malária Ministério da Saúde, Brasília 2001
12. Brasil, Ministério da Saúde, Guia Prático de Tratamento da Malária no Brasil Ministério da Saúde, Brasília 2009
13. Brasil MS, Manual de diagnástico laboratorial da malária Ministério da Saúde, Brasília 2005 112
14. Análise da freqüência de recaídas de malária por Plasmodium vivax em região não endêmica. Boulos M, Amato Neto V, Dutra AP, Di Santi SM, Shiroma M, Rev Inst Med Trop Sao Paulo 1991 33 143 146 10.1590/S0036-46651991000200009 1844384
15. Association of subtherapeutic dosages of a standard drus regimen with failures in preventing relapses of vivax malaria. Duarte EC, Pang LW, Ribeiro LC, Fontes CJF, AmJTrop Med Hyg 2001 65 471 476
16. Adequate primaquine for vivax malaria. Kitchener S, Nasveld P, Bennett S, Torresi J, J Travel Med 2005 12 133 135 15996441
17. Clinical features of malaria. Warrell DA, Essential Malariology Oxford University Press, New York, Warrell DA, Gilles HM, 4 2002 192
18. Plasmodium species (Malaria). Fairhurst RM, Wellems TE, Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases Churchill Livingstone, New York, Mandell GL, Bennett JE, Dolin R, 7 2009 3437 3462
19. Case Report: an unusual late relapse of Plasmodium vivax malaria. Mangoni ED, Severini C, Menegon M, Romi R, Ruggiero G, Majori G, AmJTrop Med Hyg 2003 68 159 160
20. Determinants of relapse periodicity in Plasmodium vivax malaria. White NJ, Malar J 2011 10 297 10.1186/1475-2875-10-297 21989376
21. Chloroquine resistant Plasmodium vivax from Indonesia. Schwartz IK, Lackritz EM, N Engl J Med 1991 324 927 2000122
22. Plasmodium vivax resistance to chloroquine? Rieckmann H, Davis DR, Hutton DC, Lancet 1989 334 1183 1184 10.1016/S0140-6736(89)91792-3
23. The genetic diversity of Plasmodium vivax populations. Ananias LC, Escalante A, Imwong M, Snounou G, Trends Parasitol 2003 19 220 226 10.1016/S1471-4922(03)00085-0 12763428
24. Self-reported compliance with last malaria treatment and occurrence of malaria during follow-up in a Brazilian Amazon population. Duarte EC, Gyorkos TW, Trop Med Int Health 2003 8 518 524 10.1046/j.1365-3156.2003.01042.x 12791057
25. How do patients use antimalarial drugs? A review of the evidence. Yeung S, White NJ, Trop Med Int Helath 2005 10 121 138 10.1111/j.1365-3156.2004.01364. x
26. Compliance with 14-day primaquine therapy for radical cure of vivax malaria-a randomized placebo-controlled trial comparing unsupervised with supervised treatment. Leslie T, Rab MA, Ahmadzai H, Durrani N, Fayaz M, Kolaczinski J, Rowland M, Trans R Soc Trop Med Hyg 2004 98 168 173 10.1016/S0035-9203(03)00041-5 15024927
27. Adherence to antimalarial drug therapy among vivax malaria patients in Northern Thailand. Khantikul N, Butraporn P, Kim HS, Leemingsawat S, Tempongko MASB, Suwonkerd W, J Health Popul Nutr 2009 27 4 13 19248643
28. Pedro RS, Tratamento farmacolágico da malária em um instituto de pesquisa clínica no Rio de Janeiro. MSc Thesis Fundação Oswaldo Cruz, Instituto de Pesquisa Clínica Evandro Chagas, Rio de Janeiro 2011
29. Concurrent and predictive validity of a self-reported measure of medication adherence. Morisky DE, Green LW, Levine DM, Med Care 1986 24 67 73 10.1097/00005650-198601000-00007 3945130
30. Quality of essential drugs in tropical countries: evaluation of antimalarial drugs in the Brazilian Health System. Nogueira FHA, Moreira-Campos LM, Santos RLC, Pianetti GA, Rev Soc Bras Med Trop 2011 44 582 586 10.1590/S0037-86822011000500010 22031073
31. In vitro dissolution profile of primaquine tablets available for malaria treatment in Brazil. Rodrigues LNC, Watanabe SP, Ferraz HG, Rev Soc Bras Med Trop 2008 41 41 45 10.1590/S0037-86822008000100008 18581646
32. A importncia de uma unidade sentinela de vigilncia em malária na região extra-amazônica, referência para viajante. Brasil P, Guaraldo L, Boletim Farmacovigilncia 2007 4 2 21779687
33. Primaquine for preventing relapses in people with Plasmodium vivax malaria. Galappaththy GNL, Omari AAA, Tharyan P, Cochrane Database of Syst Rev 2007 Issue 1 D004389 10.1002/14651858.CD004389.pub2
34. Pharmacokinetics of primaquine in man. II. Comparison of acute vs chronic dosage in Thai subjects. Ward SA, Mihaly GW, Edwards G, Looareesuwan S, Phillips RE, Chanthavanich P, Warrell DA, Orme MLE, Breckenridge AM, Br J Clin Pharmac 1985 19 751 755 10.1111/j.1365-2125.1985.tb02710.x
35. Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Mihaly GW, Ward SA, Edwards G, Nicholl DD, Leorme M, Breckenridge AM, Br J Clin Pharmac 1985 19 745 750 10.1111/j.1365-2125.1985.tb02709.x
36. Monitoring of clinical efficacy and in vitro sensitivity of Plasmodium vivax to chloroquine in area along Thai Myanmar border during 2009-2010. Muhamad P, Ruengweerayut R, Chacharoenkul W, Rungsihirunrat K, Na-Bangchang K, Malar J 2011 10 44 10.1186/1475-2875-10-44 21324161
37. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Wells TNC, Burrows JN, Baird JK, Trends Parasitol 2010 26 145 151 10.1016/j.pt.2009.12.005 20133198
38. Avaliação da resposta aos esquemas de tratamento reduzidos para malária vivax. Abdon NP, Pinto AYN, Silva RSU, Souza JM, Rev Soc Bras Med Trop 2001 34 343 348 11562727
39. Short report: a consideration of primaquine dose adjustment for radical cure or Plasmodium vivax malaria. Schwartz E, Regev-Yochay G, Kurnik D, AmJTrop Med Hyg 2000 62 393 395
40. Subdoses of primaquine in overweight patients and malaria vivax relapses: report of two cases in the Federal District, Brazil. Santos JB, Luz FCO, Deckers FAL, Tauil PL, Rev Soc Bras Med Trop 2010 43 749 750 10.1590/S0037-86822010000600033 21181040
41. World Health Organization, Guidelines for the treatment of malaria WHO, Geneva 2010
42. Guidelines for Treatment of Malaria in the United States, CDC 2001 http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf
43. UK malaria treatment guidelines. Laloo DG, Shingadia D, Pasvol G, Chiodini PL, Whitty CJ, Beeching NJ, Hill DR, Warrell DA, Bannister BA, J Infect 2007 54 111 121 10.1016/j.jinf.2006.12.003 17215045
44. Centre for Disease Control, Malaria guidelines for health professionals in the northern territory CDC, Australia 5 2007
45. Primaquine in vivax malaria: an update and review on management issues. Fernando D, Rodrigo C, Rajapakse S, Malar J 2011 10 351 10.1186/1475-2875-10-351 22152065